IDEXX Laboratories Inc. (Nasdaq: IDXX) has developed a diagnostic test to help veterinarians detect kidney injury in cats and dogs at an earlier stage to improve treatment.
The Westbrook-based provider of veterinary diagnostics and software said it will start using the Cystatin B Test starting later this year in the United States and Canada, with plans to introduce the test in Europe in 2024.
“We are pleased to offer the industry’s first biomarker for kidney injury,” said Jay Mazelsky, the company’s president and CEO. “The IDEXX portfolio of tests and technologies enables veterinarians to intervene earlier, advance treatment and now detect kidney injury, resulting in better outcomes throughout the lives of their patients.”
A recent company survey shows that as many as 1 of 3 kidney cases seen by veterinarians are related to kidney injury, with subtle or nonspecific signs making diagnosis difficult. The new test aims to help veterinarians overcome those challenges.
The new test is slated to uncover clinical insights for an estimated 2 million patient visits annually, IDEXX said.
Kidneys regulate blood pressure, electrolyte balance and red blood cell production, and remove toxins. For veterinarians treating cats and dogs, IDEXX said its new test will enhance their view into kidney health by detecting injury and subtle changes in kidney function.
IDEXX said the test has been endorsed by the American College of Veterinary Nephrology and Urology and the International Renal Interest Society.
“As nephrologists, we anxiously await this new era of early disease discovery and management,” the international group was cited by IDEXX as saying.
Financial results and market cap
In May, IDEXX posted first-quarter results that exceeded Wall Street estimates and raised its 2023 full-year financial outlook.
IDEXX shares have an equity value of more than $40 billion, based on Friday’s closing price on Nasdaq of $483.03 per share. The stock is trading 47% higher than a year ago.